{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DNTH",
  "name": "Dianthus Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/DNTH/",
  "json_url": "https://frontierpicks.com/dossiers/DNTH.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Complement re-rate has gone quiet: no company disclosure since the 2026-08-04 Q2 print, a fresh 52-week high at $115.96 on a lower RSI than the early-August one, and the next dated binary — MoMeNtum MMN top-line — not until December 2026. Roughly three months of empty calendar between here and the readout.",
  "invalidation_trigger": "A weekly close below $100 fails the July breakout shelf (2026-07-09 close $100.03) and returns price to the pre-breakout base; secondary conditions: a company update dating CAPTIVATE Part B top-line in 2H'27 or later, or the December MoMeNtum MMN top-line arriving without a clean primary hit.",
  "catalyst_date": "2026-05-04",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "oncology-immunology",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Single molecule: claseprubart carries CIDP, gMG. One negative randomized readout reprices all three the same day; no second clinical asset cushions it.",
    "Q2 language guides to CAPTIVATE Part B top-line GUIDANCE by year-end 2026 — that is a date for the date, not the data itself.",
    "No product revenue. The $0.761M reported in Q2 2026 is collaboration income; the company is funded by the balance sheet, not by sales.",
    "~$1.2B cash at 2026-06-30 with runway into 2030, but the S-3 shelf is live — an equity take-down near highs is not precluded by runway guidance.",
    "Aggregator 'average price target' figures for DNTH diverge widely by provider and analyst count; check the analyst count before citing any consensus number."
  ],
  "body_markdown": "## Current Thesis\n\nTwo weeks of silence have followed the loudest fortnight of the year. Since the 2026-08-04 Q2 print and the DNTH312 announcement the same day, no company disclosure has reached the tape; the most recent DNTH-linked item located is third-party — Agomab's 2026-08-10 release proposing Dianthus president and CEO Marino Garcia to its own board. Into that vacuum the stock still marked a new 52-week high of $115.96 and closed 2026-08-21 at $111.10, 4.2% below it, with a three-month price change of +28.5%.\n\nThe narrative leg an investor is buying is unchanged from the July and early-August coverage: claseprubart (DNTH103), an antibody selective for activated C1s that shuts the classical complement pathway while leaving the lectin and alternative arms intact, carries CIDP, gMG and MMN on a single molecule, funded by roughly $1.2B of cash at 2026-06-30 with runway guided into 2030. What has changed is the calendar's shape. The first randomized-era readout, MoMeNtum in multifocal motor neuropathy, is guided to December 2026 on 46 enrolled patients against a 36-patient target. CAPTIVATE Part B still has no top-line date — the 2026-08-04 language commits only to *guidance on timing* by year-end 2026.\n\nRSI(14) reads 56.6 at $111.10 against 59.5 at the 2026-08-07 close of $108.92. Measured: the higher price carries a lower oscillator. Inferred, and it is an inference: participation behind the August leg is moderating rather than broadening.\n\n## Bull Case\n\n- **Structure held through a news vacuum.** The 52-week high advanced from $112.64 (pre-2026-08-08) to $115.96 with no fresh company disclosure in between — the August re-rate has not given back the July breakout zone (2026-07-09 high $102.24, close $100.03).\n- **A readout now exists inside 2026.** MoMeNtum finished enrolling at 46 patients versus a 36-patient target, top-line \"on track for December '26\" per the 2026-08-04 release. Before August, the nearest randomized datapoint was undated.\n- **Part A interim survived restatement.** 75% response rate in the first 40 CAPTIVATE Part A completers against a ≥50% GO threshold, with no related serious infections, no clinical symptoms of drug-induced lupus and no safety discontinuations (2026-08-04). The early GO itself came 2026-03-09 on 20 confirmed responders with fewer than 40 planned participants.\n- **Balance sheet removes financing urgency.** ~$1.2B cash at 2026-06-30 against Q2 R&D of $48.7M and G&A of $13.6M; runway guided into 2030.\n- **Pipeline widened on 2026-08-04.** DNTH312, a bifunctional fusion of claseprubart and TACI targeting aC1s plus BAFF/APRIL, is targeted Phase 1 ready by year-end 2027; DNTH212 Phase 1 healthy-volunteer data is anticipated by year-end 2026; EMERGE, the gMG Phase 3, was announced initiated 2026-06-29.\n- **Sell-side marks sit above spot.** Evercore ISI $134 (2026-08-03), Wedbush $122 (2026-08-05), Truist $128 from $110 (2026-08-06), HC Wainwright $158 (2026-08-06).\n\n## Bear Case\n\n- **The mechanism question is unresolved.** Sanofi's riliprubart, the same selective anti-activated-C1s approach, had MOBILIZE halted on 2026-06-10 for insufficient efficacy in refractory CIDP. Dianthus's GO decision rests on open-label responder data with no placebo arm; only Part B settles the comparison, and Part B has no date.\n- **Guidance about guidance.** A November or January update dating Part B top-line in 2H'27 or later would extend the thesis by a full year without any negative clinical datapoint.\n- **Nothing is dated for roughly three months.** The Q1 print landed 2026-05-05 and Q2 on 2026-08-04, implying early November for Q3. Between 2026-08-22 and the December window there is no company-scheduled event on the record.\n- **No product revenue.** The $0.761M booked in Q2 2026 is collaboration income. Q2 net loss was $50.2M, or $(0.90) per share, against $31.6M and $(0.88) in Q2 2025 on 56,029,124 weighted-average shares.\n- **The shelf is live.** The March 2026 underwritten offering priced at $81.00 — Runway into 2030 does not preclude a take-down while the stock trades near a 52-week high.\n- **The broker cluster is behind the move.** All four target raises fall inside 2026-08-03 to 2026-08-06, after the June–July advance off roughly $82.\n\n## Setup & Price Structure\n\nReference levels, all from the adjusted daily series through 2026-08-21: last close $111.10; 52-week high $115.96; distance from that high -4.2%; three-month price change +28.5%; RSI(14) 56.6. The July shelf that defines the breakout sits at the 2026-07-09 high of $102.24 and close of $100.03. The 2026-08-03 inducement grants — carry a $106.02 exercise price, a dated marker of where the stock traded at the start of the month.\n\n**The narrative is maturing.** The attention arrived and has already been priced: four target raises inside four sessions (2026-08-03 → 2026-08-06), a Q2 print with two new disclosures on 2026-08-04, and then nothing company-sourced for the following seventeen calendar days while price ground to a marginal new high on a lower oscillator reading. That is not the expanding-headline pattern of accelerating, and no evidence of mainstream or retail-forum saturation was found in the sources searched, so saturated is not supported either.\n\nCrowding and positioning, stated as observables rather than a verdict: the target-raise cluster is concentrated in a single week and no raise dated after 2026-08-06 was located; the S-3 shelf remains available with the last close well above the $81.00 March take-down price; the most recent insider transactions located are CFO Ryan Savitz selling 8,224 shares for approximately $739,000 on 2026-04-09 under a 10b5-1 plan and director Paula Soteropoulos exercising 599 options at $8.44 and selling at $80.11 on 2026-03-31 — nothing newer surfaced. No earnings date falls inside the next 30 days.\n\n## Catalyst Calendar (next 30 days)\n\nThe 2026-08-22 → 2026-09-21 window contains no company-dated event on the public record. Nearest dated items, all beyond the window:\n\n- **~2026-11-05 (est.)** — Q3 2026 results. Q1 landed 2026-05-05, Q2 on 2026-08-04, so early November is the pattern-implied date. The live question is whether CAPTIVATE Part B top-line finally receives a calendar entry.\n- **~2026-12-01 (est.)** — MoMeNtum Phase 2 MMN top-line, 46 patients, guided \"December '26\".\n- **~2026-12-31 (est.)** — CAPTIVATE Part B top-line *timing* guidance, promised by year-end 2026.\n- **~2026-12-31 (est.)** — DNTH212 Phase 1 healthy-volunteer data, anticipated by year-end 2026.\n- **2028-07-01 (guided 2H'28)** — EMERGE gMG Phase 3 top-line.\n\n## What Would Change Our Mind\n\nThe structure that has to hold is the July shelf. Losing it would mean the August advance — made on a print that added no efficacy data, plus four target raises — round-tripped into the pre-breakout base with the December readout still ahead: a weekly close below $100 marks that break. Above that level the drift is intact even with an empty calendar.\n\nThree non-price conditions carry equal weight. First, a Q3 or January update that dates Part B top-line in 2H'27 or later, or repeats \"guidance expected\" without a date — the duration of the entire thesis is set by that sentence. Second, the December MoMeNtum top-line coming and going without a clean primary hit; MMN is commercially small, but it is the same molecule that carries CIDP and gMG. Third, a 424B5 prospectus supplement, an ATM sales agreement or an overnight block at a discount to the prior close, which would put supply into the high rather than leaving the shelf dormant.\n\nWhat would strengthen the case rather than break it: a dated Part B top-line inside 2026 or 1H'27, or clean DNTH212 Phase 1 human data landing before year-end and broadening the story off one molecule.\n\n## Correlation Notes\n\n- **Same-mechanism read-across.** Sanofi's riliprubart is the closest comparator; the 2026-06-10 MOBILIZE halt in refractory CIDP is the reason the randomized Part B question is priced as a genuine binary rather than a formality. Any further Sanofi disclosure on that program moves DNTH without DNTH filing anything.\n- **FcRn class in CIDP.** Approved FcRn agents set the competitive share ceiling in the indication; sell-side revisions to DNTH peak-sales assumptions that cite FcRn uptake would compress the terminal value independent of trial outcome.\n- **Clinical-stage biotech beta.** No product revenue means the multiple between events is set by sector risk appetite and rates. Between 2026-08-22 and December, price action here is more likely to track XBI-type flows than anything company-specific, since the company has scheduled nothing.\n- **Single-molecule concentration.** CIDP, gMG and MMN share claseprubart, so the three programs are not independent draws; DNTH312 and DNTH212 are too early to offset a negative randomized result.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-22T08:09:51+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}